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ORIGINAL ARTICLE
Protective effects of sodium thiosulfate for cisplatin-mediated
ototoxicity in patients with head and neck cancer
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AKIRA TSUJI2, KAZUHIRA ENDO2, SATORU KONDO2, NAOHIRO WAKISAKA2,
SHIGEYUKI MURONO2, MAKOTO ITO3 & TOMOKAZU YOSHIZAKI2
1Otolaryngology-Head and Neck Surgery, Toyama Prefectural Hospital, Toyama, 2Department of Otolaryngology-Head
and Neck Surgery, Kanazawa University Graduate School of Medical Science, Kanazawa and 3Pediatric
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Abstract
Conclusions: Intra-arterial high-dose cisplatin chemoradiation (CRT-IA) with sodium thiosulfate (STS) causes relatively less
severe cisplatin ototoxicity than intravenous cisplatin chemoradiation without STS (CRT-IV). The results of this study also
suggest that early detection of ototoxicity is possible by testing the hearing loss at ultra-high frequencies. Objectives: To
investigate protective effects of STS against cisplatin ototoxicity.Methods: Between 2011 and 2013, 18 patients with head and
neck carcinomas were treated with intra-arterial infusions of high-dose cisplatin (range 100–180 mg/body, mean 111 mg/body;
range 2–5 courses, mean 3.6 courses) and systemic administration of cisplatin (range 66–185 mg/body, mean 130 mg/body;
range 1–3 courses, mean 2.6 courses) and concurrent radiation therapy (range 60–70 Gy, mean 69 Gy). Cisplatin was
neutralized by STS in CRT-IA but not in CRT-IV. Results: Intra-arterial infusion in the high-dose cisplatin group caused
signiﬁcant hearing loss at ultra-high frequencies of 10 and 12 kHz (p = 0.028, 0.039, respectively), whereas the group receiving
systemic administration of cisplatin had signiﬁcant hearing loss at high frequencies of 8 and 10 kHz (p = 0.016, 0.027,
respectively).
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Introduction
Head and neck squamous cell carcinoma (HNSCC)
is the sixth most common cancer worldwide [1].
Although HNSCC has a good prognosis after surgi-
cal therapy or irradiation in the early stages,
advanced HNSCC has a poor prognosis. Cisplatin
is a potent radiosensitizer, and is widely accepted as
the standard of care in combined chemoradiotherapy
in HNSCC [2,3]. The concurrent use of cisplatin-
based chemotherapy with radiotherapy has been
shown to improve the response rates. It also facil-
itates organ preservation in patients with advanced
HNSCC.
Cisplatin induces monoadducts at nucleophilic
sites and can subsequently lead to intrastrand and
interstrand cross links in DNA. Once formed, these
lesions can trigger apoptotic cascades, predominantly
via the mitochondrial pathway. Similar events are
observed in non-cancer cells [4]. The dose of cisplatin
is an important determinant of the extent of cytotox-
icity. To increase drug doses in the tumor while
maintaining minimal systemic toxicity and overcom-
ing the chemoradioresistance of a tumor, supradose
cisplatin infusion via superselective intra-arterial
chemotherapy was designed. This was achieved by
using microcatheters placed angiographically to
permit superselective rapid infusions while sodium
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thiosulfate (STS) is systemically infused to protect
against cisplatin toxicity.
The signiﬁcant results of radiotherapy and concom-
itant intra-arterial cisplatin (RADPLAT), a concur-
rent supradose intra-arterial infusion of cisplatin
(150 mg/m2, four courses) with radiotherapy used
against advanced HNSCC, were ﬁrst reported by
Robbins et al. in 1994 [5]. The systemic toxicity of
RADPLAT is less severe than that of standard sys-
temic chemotherapy protocols [5,6]. Previously, we
reported the efﬁcacy of our modiﬁed protocol of
RADPLAT, termed the Kanazawa regimen (cisplatin
150 or 100 mg/body intra-arterially (IA) and STS
14 g/m2 intravenously (IV), two to three courses,
radiotherapy 2 Gy/fraction, 66 Gy). To increase the
completion rate of the regimen, our protocol treated
patients with a cisplatin dose lower than that used in
the RADPLAT protocol. The feasibility of our pro-
tocol was better than that of RADPLAT. Moreover,
the overall, local disease-free, and progression-free
survival rates did not show signiﬁcant differences
despite the reduced doses and frequencies.
We have formulated a treatment using the Kana-
zawa regimen, and have assessed nephrotoxicity,
hematologic toxicity, and mucosal events in detail.
However, we have not evaluated ototoxicity in this
regimen. In the present study, we compared the
incidence of hearing loss in patients treated with
the Kanazawa regimen and intravenous cisplatin che-
moradiation without STS. We also compared the
extent of cisplatin ototoxicity due to the Kanazawa
regimen with that caused by RADPLAT [7].
Material and methods
Patients and treatment
Between 2011 and 2013, 18 patients with HNSCC
were treated with intra-arterial infusion of high-dose
cisplatin (range 100–180 mg/body, mean 111 mg/
body, range 2–5 courses, mean 3.6 courses) or sys-
temic administration of cisplatin (range 66–185 mg/
body, mean 130 mg/body, range 1–3 courses, mean
2.6 courses) with concurrent radiation therapy (range
60–70 Gy, mean 69 Gy). STS (14 g/m2/4 h) was
simultaneously administered IV for cisplatin neutral-
ization. All patients signed an informed consent.
Group 1 (intra-arterial infusion of high-dose cisplatin)
consisted of seven patients (all males). Group 2 (sys-
temic administration of cisplatin) comprised
11 patients (9 males and 2 females). All patients
received radiation treatment. Two patients had dis-
tant metastasis. Patients with ear pathology, history of
acoustic/noise exposure, trauma, history of middle
and inner ear surgery, and those who were taking
any ototoxic drugs were excluded from the study. All
included patients gave a detailed medical history and
underwent clinical and hearing examination in addi-
tion to blood and urine analyses.
Audiologic assessment
Before the start of chemotherapy, baseline hearing
threshold data (up to 12 kHz) were obtained by a
pure-tone audiometer installed in a sound-proof
room in the otolaryngology department. Air conduc-
tion (AC) thresholds were measured at frequencies of
0.125, 0.25, 0.5, 1, 2, 4, 8, 10, and 12 kHz; bone
conduction (BC) thresholds were measured at 0.5, 1,
2, and 4 kHz. Patients were reassessed 1–3 weeks after
the last cisplatin infusion. The frequency spectrum of
hearing loss was recorded for each subject.
Statistical methods
The data were analyzed using SPSS version 19. The
Mann–Whitney U test was performed to compare the
hearing abilities between the patients administered
intra-arterial infusion of high-dose cisplatin and those
given systemic administration of cisplatin. Ototoxicity
was deﬁned as hearing loss of 20 dB at one frequency.
After chemotherapy, an increase of 20 dB above the
baseline hearing threshold for an individual frequency
was considered signiﬁcant. During baseline audiom-
etry, a frequency with an absent response was
excluded from the observations.
Results
In this study, the patient age ranged from 45 to
82 years, with a majority aged 50–60 years. The
mean age of presentation was 63 years. The male
to female ratio was 8:1 (Table I). The hearing levels
were worsened by a statistically signiﬁcant margin
after chemotherapy at ultra-high frequencies of 8,
10, and 12 kHz (p = 0.012, 0.002, 0.011, respectively,
Wilcoxon signed rank test). The threshold shifts at
low and high frequencies (0.125–4 kHz) were not
observed after therapy (Figure 1). During follow-up
visits, two patients presented with subjective hearing
loss and tinnitus at the ﬁrst follow-up. Both of them
were from group 2 (a 69-year-old male and a 56-year-
old male). There was no statistical correlation
between age and dose of cisplatin. There was no
subjective or objective vertigo in any patient. Patients
in group 1 had a mean age of 67 years and were
treated with intra-arterial infusions of high-dose cis-
platin. In this group, they had signiﬁcant hearing loss
according to the Wilcoxon signed rank test scale, and
this loss was observed at ultra-high frequencies of
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10 and 12 kHz (p = 0.028, 0.039, respectively,
Figure 2). The ototoxicity could only be observed
in the ultra-high frequencies. There was minimal or
no hearing loss at frequency £ 8 kHz. Group 2 had a
mean age of 61 years and was treated with systemic
administration of cisplatin. In this group, patients had
signiﬁcant hearing loss according to the Wilcoxon
signed rank test scale, and this loss was observed at
ultra-high frequencies of 8 and 10 kHz (p = 0.016,
0.027, respectively, Figure 3). The ototoxicity was
only observed at the high and ultra-high frequencies.
There was minimal or no hearing loss at
frequencies £ 4 kHz.
Discussion
Platinum drugs are essential components in chemo-
therapeutic regimens for HNSCC. The clinical
administration of cisplatin is limited by its side effects,
including ototoxicity. It is presumed that the basic
mechanisms of platinum-induced cytotoxicity in the
inner ear are not completely different from those in
tumor cells. Cisplatin acts in the cell via many
mechanisms, such as DNA damage and the produc-
tion of reactive oxygen species, which lead to pro-
grammed cell death by apoptosis. Cell death can also
occur via necrosis when cells are exposed to high
concentrations of cisplatin [8]. A factor speciﬁcally
associated with inner ear damage is drug uptake from
the stria vascularis into the cochlear ﬂuids and hair
cells. Systemic platinum is trafﬁcked across the
Table I. Characteristics of patients (n = 18) and treatment.
Characteristic Group 1 Group 2 Entire study group
Age (years)
Median 67 61 63
Range 57–82 45–72 45–82
Sex (n)
Male 7 9 16
Female 0 2 2
Tumor site (n)
Sinus and nasal cavity 1 1 2
Nasopharynx 0 6 6
Oropharynx 2 2 4
Hypopharynx 2 1 3
Larynx 2 1 3
Cisplatin dose, mg/body (mg/m2)
Median 111.4 (72.24) 138.9 (85.6) 128.2 (80.4)
Range 100–180 (61.5–112.5) 66–185 (66.7–100) 66–185 (66.7–112.5)
Total cisplatin dose, mg/body (mg/m2)
Median 200–900 (123.1–562.5) 145–556 (100–300) 145–900 (80–562.5)
Range 123.1–562.5 80–300 80–562.5
Cisplatin infusion cycles
Median 3.6 2.6 2.9
Range 2–5 1–3 1–5
Radiation therapy dose (Gy)
Median 69.4 68.7 69
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Figure 1. Mean hearing thresholds of all patients before chemo-
therapy (.) and after chemotherapy (*).
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blood–endolymph barrier and preferentially enters
hair cells through their apical membranes [4].
Platinum-induced hearing loss initially occurs at
higher frequencies and subsequently affects the lower
ones [8]. In the present study, we observed the
hearing loss from intravenous cisplatin chemoradia-
tion without STS (CRT-IV) at high and ultra-high
frequencies. However, the hearing loss from intra-
arterial high-dose cisplatin chemoradiation (CRT-IA)
with STS was observed only at ultra-high frequencies.
The difference between CRT-IA and CRT-IV treat-
ments could be due to STS, the neutralizing agent for
cisplatin. STS is a reactive thiol agent clinically used
as an antidote to cyanide or nitroprusside poisoning.
At high molar excess, STS binds to and inactivates the
electrophilic platinum compound in vitro [9]. In
CRT-IA treatment, cisplatin is directly infused into
the nutrient artery of the tumor. STS is simulta-
neously infused systemically in the systemic admin-
istration of cisplatin. The direct intra-arterial infusion
allows the tumor bed to initially receive the full dose of
cisplatin before the neutralizing agent and allows the
systemic organs to receive the neutralizing agent
(Figure 4). It is considered that this regimen pre-
vented the hearing loss from CRT-IA at lower
frequencies.
Furthermore, the extent of hearing loss with the
Kanazawa regimen was lower than that with RAD-
PLAT. Although previous reports describing the out-
comes of clinical trials with RADPLAT did not
comment on the incidence and extent of hearing
loss due to treatment, signiﬁcant hearing loss due
to RADPLAT was shown in the studies by
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Figure 4. Cisplatin as a neutralizing agent.
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shifts derived from data recorded after RADPLAT.
The shifts ranged below 5 dB at frequencies below
2 kHz. However, the noted hearing losses were
observed at frequencies above 4 kHz, 15 dB at
4 kHz and 23.2 dB at 8 kHz. On the other hand,
in our data, the mean thresholds of the AC after CRT-
IA at frequencies below 8 kHz were almost the same
as those before CRT-IA. Zuur et al. also reported
hearing loss caused by intra-arterial cisplatin chemor-
adiation, particularly at ultra-high frequencies [11]. In
their study, the mean total threshold shift at PTA AC
8, 10, and 12.5 kHz was 20.4 dB for CRT-IA. The
present study showed that the mean total threshold
shift at PTA AC 8, 10, and 12 kHz was only 6.9 dB for
CRT-IA. STS was administered in the cases studied
by Madasu et al. and Zuur et al. [10,11]. The
relatively lesser extent of hearing deterioration in
our regimen may be explained by the use of a lower
dose of cisplatin than used in RADPLAT. The inci-
dence and extent of ototoxicity caused by cisplatin are
associated with cumulative cisplatin [4]. In the pres-
ent study, the median dose per infusion of cisplatin
was 111 mg, less than 80 mg/m2. In contrast, in the
cases of Madasu et al. and Zuur et al., who followed
the RADPLAT protocol, the dose per infusion of
cisplatin was 150 mg/m2 [10,11]. The median dose
per infusion of cisplatin was 267 mg/m2 in the report
by Zuur et al. [11]. The ﬁnal difference in cumulative
cisplatin after therapy between our protocol and
RADPLAT was over 600 mg. The lower dose of
cisplatin appears to have contributed to the smaller
extent of ototoxicity.
On the other hand, we detected hearing loss in
CRT-IA only at ultra-high frequencies of 10 and
12 kHz in the present study. Cisplatin ototoxicity
has been identiﬁed to cause hearing loss, beginning
at the higher frequencies and, with increasing doses or
prolonged treatment, progressively extending to lower
frequencies [12]. So typical audiologic assessment
(frequencies of 0.125, 0.25, 0.5, 1, 2, 4, 8 kHz) could
not detect hearing loss in patients who received CRT-
IA. The results of the present study show the possi-
bility that testing ultra-high frequencies enables us to
detect early ototoxicity by cisplatin. Early detection of
ototoxicity would be helpful in protecting against
ototoxicity and treating patients with consideration
of their quality of life.
A major toxic effect of cisplatin nephrotoxicity may
be avoided with adequate hydration and diuresis; the
major hematological toxicities may be reduced with
administration of bone marrow growth factors.
However, there appears to be no effective medical
treatment for limiting or preventing ototoxicity.
Therefore, it is very important to prevent or reduce
the cisplatin-associated ototoxicity without decreasing
tumor cytotoxicity. In the present study, we showed
reduced cisplatin ototoxicity resulting from our intra-
arterial infusion protocol using STS, the neutralizing
agent for cisplatin.
Conclusion
The hearing loss from CRT-IA was only observed at
ultra-high frequencies. On the other hand, a wider
range of frequency-associated hearing loss was
observed with CRT-IV. This suggests that the
intra-arterial infusion protocol presents with a
relatively lesser extent of cisplatin ototoxicity. This
difference between CRT-IA and CRT-IV could be
caused by STS, the neutralizing agent for cisplatin.
The results of this study also suggest that early
detection of ototoxicity is possible by detecting early
hearing loss at ultra-high frequencies.
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